<DOC>
	<DOCNO>NCT00617695</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety Zolmitriptan ( Zomig ) nasal spray , 5.0 mg , compare placebo ( inactive drug ) 2 migraine headache 3-month period adolescent patient ( age 12 17 year ) migraine headache</brief_summary>
	<brief_title>Efficacy Zolmitriptan ( Zomig ) Treatment Migraines Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Adolescents age 1217 year time screen . Patients must enrol turn 18 year age within 12 week randomization . An establish diagnosis migraine least 1 year ; minimum 2 migraine , consider moderately/severely disable , per month average school year A history usual migraine duration &gt; 2hours untreated 3 month prior screen A history basilar , ophthalmoplegic hemiplegic migraine headache potentially serious neurological condition associate headache clinically significant abnormality indicate medical history , physical exam etc Has use monoamine oxidase inhibitorA ( MAOA ) , methysergide , methylergonovine cimetidine 2 week randomization . Evidence ischemic heart disease , arrhythmia , accessory conduction pathway disorder determine central cardiologist use predetermine agree upon pediatric standard ; Has uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Zolmitriptan</keyword>
	<keyword>ZOMIG</keyword>
	<keyword>migraine</keyword>
	<keyword>headache response</keyword>
	<keyword>headache</keyword>
	<keyword>headache pain</keyword>
</DOC>